- Home
- IBRX vs BATRA Comparison
IBRX vs BATRA Comparison
Compare IBRX & BATRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IBRX
- BATRA
- Stock Information
- Founded
- IBRX 2014
- BATRA 1991
- Country
- IBRX United States
- BATRA United States
- Employees
- IBRX N/A
- BATRA N/A
- Industry
- IBRX Biotechnology: Biological Products (No Diagnostic Substances)
- BATRA Broadcasting
- Sector
- IBRX Health Care
- BATRA Industrials
- Exchange
- IBRX Nasdaq
- BATRA Nasdaq
- Market Cap
- IBRX 2.4B
- BATRA 2.6B
- IPO Year
- IBRX N/A
- BATRA N/A
- Fundamental
- Price
- IBRX $2.87
- BATRA $49.07
- Analyst Decision
- IBRX Strong Buy
- BATRA Strong Buy
- Analyst Count
- IBRX 5
- BATRA 2
- Target Price
- IBRX $11.40
- BATRA $56.50
- AVG Volume (30 Days)
- IBRX 10.1M
- BATRA 55.8K
- Earning Date
- IBRX 08-11-2025
- BATRA 08-07-2025
- Dividend Yield
- IBRX N/A
- BATRA N/A
- EPS Growth
- IBRX N/A
- BATRA N/A
- EPS
- IBRX N/A
- BATRA N/A
- Revenue
- IBRX $31,222,000.00
- BATRA $672,879,000.00
- Revenue This Year
- IBRX $567.98
- BATRA $8.81
- Revenue Next Year
- IBRX $160.56
- BATRA $5.01
- P/E Ratio
- IBRX N/A
- BATRA N/A
- Revenue Growth
- IBRX 10238.41
- BATRA 4.04
- 52 Week Low
- IBRX $1.83
- BATRA $38.67
- 52 Week High
- IBRX $7.63
- BATRA $49.47
- Technical
- Relative Strength Index (RSI)
- IBRX 49.40
- BATRA 79.66
- Support Level
- IBRX $2.77
- BATRA $45.06
- Resistance Level
- IBRX $3.24
- BATRA $45.82
- Average True Range (ATR)
- IBRX 0.23
- BATRA 0.93
- MACD
- IBRX -0.03
- BATRA 0.39
- Stochastic Oscillator
- IBRX 19.74
- BATRA 93.99
About IBRX ImmunityBio Inc.
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.
About BATRA Atlanta Braves Holdings Inc. Series A
Atlanta Braves Holdings Inc is a holding company. It operates through its wholly-owned subsidiary, which is the owner and operator of the Atlanta Braves Major League Baseball Club and the mixed-use real estate development, The Battery Atlanta, and is the operator of the Atlanta Braves Major League Baseball Club's stadium, Truist Park. The company predominantly derives revenue related to the Braves baseball franchise and Truist Park from ticket sales, concessions, local broadcasting rights, advertising sponsorships, suites and premium seat fees, retail and licensing revenue, shared MLB revenue streams, including national broadcasting rights and licensing, and other sources. The company's reportable segments include: Baseball which generates key revenue, and Mixed-Use Development.